MA39991A - Cénicriviroc pour le traitement de l'infection à vih-2 - Google Patents

Cénicriviroc pour le traitement de l'infection à vih-2

Info

Publication number
MA39991A
MA39991A MA039991A MA39991A MA39991A MA 39991 A MA39991 A MA 39991A MA 039991 A MA039991 A MA 039991A MA 39991 A MA39991 A MA 39991A MA 39991 A MA39991 A MA 39991A
Authority
MA
Morocco
Prior art keywords
cenicriviroc
infection
cvc
hiv
treatment
Prior art date
Application number
MA039991A
Other languages
English (en)
Inventor
Eric Lefebvre
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MA39991A publication Critical patent/MA39991A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Le cénicriviroc (cvc) est un antagoniste actif par voie orale de liaison du ligand se liant au récepteur de chimiokine c-c de type 5 (ccr5) et au récepteur de chimiokine c-c de type 2 (ccr2). Cvc bloque la liaison de rantes, mip-1α, and mip-1β à ccr5, et de mcp-1/ccl2 à ccr2. L'invention concerne également des méthodes de traitement de l'infection à vih-2 et d'affections associées ,comprenant l'administration de cvc.
MA039991A 2014-06-02 2015-06-02 Cénicriviroc pour le traitement de l'infection à vih-2 MA39991A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462006492P 2014-06-02 2014-06-02

Publications (1)

Publication Number Publication Date
MA39991A true MA39991A (fr) 2015-12-10

Family

ID=54767270

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039991A MA39991A (fr) 2014-06-02 2015-06-02 Cénicriviroc pour le traitement de l'infection à vih-2

Country Status (4)

Country Link
US (1) US20170105969A1 (fr)
EP (1) EP3148538A4 (fr)
MA (1) MA39991A (fr)
WO (1) WO2015187663A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526628A (ja) * 2016-08-31 2019-09-19 トビラ セラピューティクス， インコーポレイテッド セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206702B1 (fr) * 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Composé bicyclique, son préparation et utilisation
WO2004091518A2 (fr) * 2003-04-11 2004-10-28 Anormed Inc. Composes de liaison aux recepteurs de chimiokine cxcr4
JP4778420B2 (ja) * 2003-04-22 2011-09-21 アノーメッド インコーポレイティド 増強された有効性を有するケモカインレセプタ結合複素環式化合物
CA2723080A1 (fr) * 2008-05-09 2009-11-12 F. Hoffmann-La Roche Ag Composes heterocycliques antiviraux

Also Published As

Publication number Publication date
EP3148538A1 (fr) 2017-04-05
WO2015187663A1 (fr) 2015-12-10
EP3148538A4 (fr) 2018-01-17
US20170105969A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
MX2017003215A (es) Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
MX2018003179A (es) Terapia de combinación con cenicriviroc para el tratamiento de fibrosis.
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12017501921A1 (en) Novel compounds
MX390348B (es) Compuestos de benzimidazol como inhibidores de c-kit
MX2015008741A (es) Ftalazinonas e isoquinolinonas como inhibidores de cinasa rho.
MX2020004506A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
IN2015DN01156A (fr)
MX381417B (es) Inhibidores de glucosidasa.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MY201535A (en) Therapeutic compounds
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
MA39991A (fr) Cénicriviroc pour le traitement de l'infection à vih-2
PH12017501214A1 (en) Cgrp antagonist peptides
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
WO2017095918A3 (fr) Procédés de traitement du cancer au moyen d'antagonistes de rspo3